Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
Aged
Aged, 80 and over
Androstenes
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Benzamides
Dipeptides
/ therapeutic use
Heterocyclic Compounds, 1-Ring
/ therapeutic use
Humans
Lutetium
Male
Middle Aged
Neoplasm Metastasis
Nitriles
Phenylthiohydantoin
/ administration & dosage
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Radiopharmaceuticals
/ therapeutic use
Taxoids
/ administration & dosage
177Lu-PSMA-617
PSMA
cabazitaxel
mCRPC
metastases
prostate cancer
radioligand therapy
second line chemotherapy
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
04
2019
accepted:
07
06
2019
entrez:
15
8
2019
pubmed:
15
8
2019
medline:
21
8
2020
Statut:
epublish
Résumé
The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving
Identifiants
pubmed: 31410185
doi: 10.7150/thno.35759
pii: thnov09p4841
pmc: PMC6691377
doi:
Substances chimiques
177Lu-PSMA-617
0
Androstenes
0
Antineoplastic Agents
0
Benzamides
0
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
Nitriles
0
Radiopharmaceuticals
0
Taxoids
0
Phenylthiohydantoin
2010-15-3
cabazitaxel
51F690397J
Lutetium
5H0DOZ21UJ
enzalutamide
93T0T9GKNU
Prostate-Specific Antigen
EC 3.4.21.77
abiraterone
G819A456D0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4841-4848Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
Competing Interests: The University of Münster received consulting fees from ABX GmbH, Radeberg, Germany for K.R. and M.B. Additionally K.R. is scientific consultant/ advisor of ABX GmbH. The authors declare they have no conflict of interest according to the subject and matter of the present article.
Références
J Pathol. 2013 Jul;230(3):291-7
pubmed: 23420560
Oncology (Williston Park). 2014 Nov;28(11):974-80
pubmed: 25403629
Mol Cancer Ther. 2015 Jan;14(1):193-201
pubmed: 25416788
EJNMMI Res. 2015 Dec;5(1):114
pubmed: 26099227
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
J Nucl Med. 2016 Sep;57(9):1334-8
pubmed: 27056618
Clin Nucl Med. 2016 Jul;41(7):522-8
pubmed: 27088387
Oncotarget. 2016 Jun 7;7(23):34930-41
pubmed: 27145459
Nuklearmedizin. 2016 Jun 28;55(3):123-8
pubmed: 27350005
Cancer. 2017 Jan 1;123(2):253-262
pubmed: 27648814
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479
pubmed: 28337529
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454
pubmed: 28488028
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670
pubmed: 28624848
Case Rep Oncol. 2017 Jul 11;10(2):627-633
pubmed: 28868022
Oncotarget. 2017 Feb 25;8(33):55567-55574
pubmed: 28903443
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19
pubmed: 29026946
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508
pubmed: 29247284
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Cancer Sci. 2018 Sep;109(9):2937-2945
pubmed: 29989268
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061
pubmed: 30027419
BJU Int. 2019 Mar;123(3):456-464
pubmed: 30098093
World J Urol. 2018 Aug 22;:null
pubmed: 30132067
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431